New leadership to drive Huntington's disease treatment commercialization efforts
- Skyhawk Therapeutics has appointed Aaron Deves as CCO.
- Deves will lead the commercialization of SKY-0515.
- The company's focus is on Huntington's disease treatment.
Skyhawk Therapeutics has announced the appointment of Aaron Deves as Chief Commercial Officer (CCO). In this new role, Deves will be responsible for leading the commercialization efforts of SKY-0515, a treatment for Huntington's disease. His extensive background in the biotechnology sector positions him to drive strategic initiatives for bringing this innovative therapy to market.
Before joining Skyhawk Therapeutics, Aaron Deves held key positions in various leading biopharmaceutical companies. His experience includes commercial leadership roles that involved launching new therapies and developing market strategies. This background will be critical as Skyhawk Therapeutics focuses on advancing its product pipeline and addressing unmet needs in Huntington's disease treatment.
Skyhawk Therapeutics emphasizes its commitment to addressing the challenges of Huntington's disease, which currently lacks effective treatment options. With Deves at the helm of commercialization, the company aims to enhance awareness and access to SKY-0515, furthering its mission to improve the lives of affected individuals.
